ITUS Announces Issuance of Second Key Cancer Detection Technology Patent

Tailwinds’ Take: as ITUS continues to show clinical success on Cchek, protecting the IP will be critical to maintaining the incredible TAM. ITUS’ patent strategy is solidifying their position as the leading player in using a Neural Network in cancer diagnostics.

SAN JOSE, Calif., March 26, 2018 /PRNewswire/ — ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat cancer, today announced that the United States Patent and Trademark Office (“USPTO”) has issued US Patent No. 9,934,364.  This is the second and very critical patent filed by the company to protect its cancer detection technology. This patented technology is a key component of Cchek™, ITUS’ early cancer detection platform.

The patent is titled, “METHODS FOR USING ARTIFICIAL NEURAL NETWORK ANALYSIS ON FLOW CYTOMETRY DATA FOR CANCER DIAGNOSIS”, and the inventors are Dr. Amit Kumar, John Roop, and Anthony Campisi. This patent is assigned wholly to Anixa Diagnostics Corp. a wholly owned subsidiary of ITUS Corporation.

Dr. Amit Kumar, ITUS’ Chairman and CEO, stated, “The claims of this patent were allowed in November of 2017, and we are pleased that this key patent has now issued. Our approach to detecting cancer relies on monitoring an individual’s immune system to identify indicators of a tumor. By measuring subsets of circulating white blood cells using flow cytometry, and performing analysis using an Artificial Intelligence (AI) application, known as a Neural Network, we have shown that we are able to effectively identify tumor-bearing individuals. The claims of patent 9,934,364 cover the key attributes of this technology, and we expect to file for additional patent protection as the development of Cchek™ continues. We have also filed a PCT to enable broader geographic protection of our technology.”

Dr. Kumar added, “With this patent now issued, and the key technology underlying Cchek™ adequately protected, we are better positioned to enhance our discussions with potential partners and to further expand the number of potential partners throughout the world.”

ITUS will be presenting data from studies utilizing this technology at the following scientific meetings over the next two months:

  • Keystone Symposia Conference, Cancer Immunotherapy: Combinations in Montreal, Quebec. This conference is currently ongoing through March 27.
  • American Association of Cancer Research, Annual Meeting in Chicago, IL, April 14-18.
  • American Association of Immunologists Meeting in Austin, TX, May 4-8.

ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body’s immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the CchekTM platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body’s immunological response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Tailwinds’ Disclaimers & Disclosures: For a full list of disclaimers and disclosures, please visit:

TW Research's Disclaimers & Disclosures: TW Research may have been compensated for writing this article. For a full list of disclaimers and disclosures, please visit


Please enter your comment!
Please enter your name here